Pune: The effectiveness of heterologous vaccine doses of the new Covid variant is likely to appear in two months, after the trial at the Christian Medical College, Vellore, ends.
Leading Virologist Dr.
Gagandeep Kang, Professor at Christian Medical College (CMC), said the agency was nearing the end of his research at a dose of heterogous.
“After the effectiveness of the heterologous vaccine dose is known, especially if the booster with the heterogic platform expands the immune response and the ability to neutralize a variety of broader variants, it will help understand its influence on the new variant,” he told TII on Saturday.
.
In the trial of the dose of heterologue, a participant received Covaxin followed by Covishield or vice versa.
Covaxin is an inactive vaccine and covishield is a viral vector vaccine that is not coated.
Medication controller General India has approved the trial of heterologous vaccine doses in CMC in July.
The trial began in August to evaluate this combination as opposed to the second policy of the same dose as the same vaccine.
The main scientist and researcher Dr.
Winsley Rose told Tii that the purpose of the trial was to study safety and immunogenicity (the antibodies produced and effectiveness) of the heterologous vaccine against the two two-dose vaccines.
He said this was the study of two parts.